A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Latest Information Update: 23 Jul 2024
At a glance
- Drugs JNJ-69086420 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 27 Feb 2024 Planned End Date changed from 25 Sep 2025 to 26 Dec 2025.
- 27 Feb 2024 Planned primary completion date changed from 19 Mar 2025 to 26 Dec 2025.